Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S FDA
- Written by PR Newswire
- First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration
- The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ transplant (SOT) or hematopoietic cell transplant (HCT)
- If Approved, Tab-cel Would be the First Approved...
